Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals

Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals

Abstract Tixagevimab–cilgavimab was available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevention from December 2021 to January 2023, with dosing changes to reflect circulating variants. In a retrospective analysis of 597 immunocompromised individuals, incidence of SARS-CoV-2...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniela Dluzynski, Paddy Ssentongo, Cory M. Hale, Shareef K. Shaheen, Natella Maglakelidze, Jeffrey M. Sivik, Maria Paula Henao, Vernon M. Chinchilli, Catharine I. Paules
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
COVID-19
Tixagevimab–cilgavimab
Monoclonal antibody
Hematopoietic stem cell transplant
Chimeric antigen receptor (CAR)-T cell therapy
Online Access:https://doi.org/10.1038/s41598-025-02240-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-02240-3

Similar Items